News

Orca-T immunotherapy shows promising results in improving survival and reducing complications in patients with hematologic malignancies compared to traditional treatments.

A groundbreaking trial shows that combining enfortumab vedotin and pembrolizumab enhances survival rates in muscle-invasive bladder cancer patients.

PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising new hope for cancer treatment.

During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell therapy, autologous stem cell therapy, or other treatment options.

FDA fast-tracks muzastotug and pembrolizumab for metastatic colorectal cancer, showcasing promising efficacy and safety in early studies.

Roxadustat receives orphan drug designation for myelodysplastic syndromes, highlighting its potential to improve transfusion independence in patients.

FDA grants a priority voucher for Tec-Dara, showcasing significant survival benefits in relapsed/refractory multiple myeloma, enhancing treatment options.

Discover essential steps for launching a successful private medical practice, from defining your vision to securing financing and managing finances effectively.

Sacituzumab govitecan shows a favorable safety profile in treating untreated triple-negative breast cancer, with manageable adverse effects compared to chemotherapy.

A groundbreaking blood test for early breast cancer detection shows exceptional accuracy, outperforming traditional mammography, especially in dense breast tissue.

Inaregacestat shows promising results in treating desmoid tumors, significantly improving progression-free survival and reducing tumor volume in recent trials.

Erdafitinib shows promising efficacy and manageable safety in treating recurrent gliomas with F3T3 gene fusions, according to recent trial findings.

FDA approves T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.

A real-world analysis highlights elranatamab's effectiveness in relapsed multiple myeloma, showcasing response rates and survival outcomes compared with teclistamab.

New research shows that patients receiving mismatched unrelated donor stem cell transplants achieve similar survival rates, regardless of HLA matching levels.

A novel all-antibody therapy shows remarkable efficacy and safety in elderly patients with newly diagnosed multiple myeloma, achieving high response rates and MRD negativity.

A new trial shows promising results for combining niraparib and dostarlimab in treating triple-negative breast cancer with BRCA mutations.

Premenopausal women with early breast cancer favor GnRHa therapy for fertility preservation during chemotherapy, with varying acceptance based on age and hormone receptor status.

A RAD51-based assessment identifies HER2-negative breast cancer patients likely to benefit from olaparib, enhancing treatment selection and outcomes.

Real acupuncture significantly enhances cognitive health in breast cancer survivors, outperforming usual care and showing promise over sham treatments.

New data from the TRIFOUR trial show that nadunolimab plus chemotherapy offers no significant survival benefit in metastatic triple-negative breast cancer.

Discover the latest breakthroughs in oncology from major conferences, including significant findings in breast cancer and multiple myeloma treatments.

A phase 3 study is evaluating olverembatinib with chemotherapy for treating Philadelphia chromosome–positive acute lymphoblastic leukemia, showing promising efficacy and safety.

Imlunestrant shows significant progression-free survival benefits in advanced breast cancer, offering a promising treatment option for patients.

FDA approves a new treatment combining niraparib and abiraterone for BRCA2-mutated metastatic prostate cancer, enhancing patient outcomes.

Giredestrant combined with everolimus significantly improves progression-free survival in advanced ER+, HER2-negative breast cancer after CDK4/6 inhibitors.

GC012F/AZD0120 CAR T-cell therapy shows 100% response rate in newly diagnosed multiple myeloma, offering hope for diverse patient groups.

Gedatolisib combined with fulvestrant shows significant progression-free survival benefits in advanced breast cancer, regardless of prior treatment duration.